BOCA RATON, Florida,
June 8, 2015 /PRNewswire/ -- Vycor
Medical, Inc. ("Vycor") (OTCQB: VYCO), a provider of innovative and
superior surgical and therapeutic solutions, announced that it has
entered into an agreement with HealthSouth Corporation (HLS) to
make available its NeuroEyeCoach Professional Center therapy
program to participating HealthSouth hospitals, following a 3-month
trial of the therapy in two HealthSouth locations.
NeuroEyeCoach is NovaVision's eye movement compensation therapy
for those patients who have suffered a cerebral visual field
disorder as a result of a stroke or brain injury and is designed to
improve a patient's ability to scan their environment more
efficiently. The program is based on several decades of scientific
research pioneered by Professor Josef
Zihl at the Max Planck Institute in Munich that has been the subject of numerous
clinical studies. Participating HealthSouth hospitals will use the
program to treat patients while in their care. In contrast to other
clinic-based saccadic programs, NeuroEyeCoach is a full-course
therapy dedicated to cerebral visual field disorders and can be
continued by the patient in their home environment.
This agreement follows the approval by HealthSouth in late 2014
to make available its VIDIT diagnostic to their hospital network
and NovaVision is installing devices into this network. The
NovaVision VIDIT is the diagnostic component of the Company's
Vision Restoration Therapy (VRT) and is used to perform
high-resolution visual field tests to screen for central visual
field deficits commonly associated with stroke or brain injury. The
ability for Health South physicians to be able to quickly identify
visual disorders through the effective screening program is
highlighted by the fact that approximately one-third of stroke or
other brain injury patients suffer from a neurologically induced
visual disorder and if this deficit goes undetected it may
adversely impact other rehabilitation modalities. Early detection
and treatment are critical steps towards improving overall patient
care, a key objective of HealthSouth.
Once diagnosed, patients are able to be treated in-clinic with
NeuroEyeCoach and referred to NovaVision for treatment following
discharge at home using VRT, which is the only FDA cleared
clinically supported therapy targeted at the restoration of lost
vision resulting from neurological brain damage such as that
resulting from stroke.
HealthSouth (www.healthsouth.com) is one of the largest
providers of post-acute healthcare services in the U.S. These two
agreements therefore provide NovaVision with a source of
installation and rental income but equally as important is a
potentially large source of patients; most stroke patients will
touch a rehabilitation center at some point and HealthSouth is the
largest network of stroke rehabilitation hospitals in the U.S.
This announcement follows NovaVision's press release in March
that it had completed development of VRT 7.0, re-engineering the
therapy to be internet-delivered and streamlining business process
to enable a significant reduction in cost to the patient.
NovaVision will provide VRT and NeuroEyeCoach in one therapy suite.
NovaVision will very shortly be commencing accepting patients with
the new therapy suite which is considered by management to be the
most affordable, clinically supported, comprehensive therapy suite
available on the market to address visual disorders arising from
stroke or brain injury.
About Vycor Medical, Inc.
With corporate headquarters in Boca
Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly
traded company (OTCQB: VYCO) dedicated to providing the medical
community with innovative and superior surgical and therapeutic
solutions and has a growing portfolio of FDA cleared medical
solutions that are changing and improving lives every day. The
Company operates two business units: Vycor Medical and NovaVision,
both of which adopt a minimally or non-invasive approach. Both
technologies have exceptional sales growth potential, address large
potential markets, have the requisite regulatory approvals and are
commercialized and generating revenue.
Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a
suite of clear cylindrical minimally invasive disposable devices
that hold the potential for speedier, safer and more economical
brain surgeries and a quicker patient discharge. VBAS is
designed to optimize neurosurgical site access, reduce patient
risk, accelerate recovery and add tangible value to the
professional medical community. The company is ISO 13485:2003
compliant, has U.S. FDA 510(k) clearance for brain and spine
surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe
(EU – Class III), Korea and Japan
and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's
VBAS see VBAS Video.
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration Therapy®
(VRT) platform is clinically supported to improve lost vision
resulting from stroke, traumatic brain injury ("TBI"), or other
acquired brain injuries. VRT is the only FDA 510K cleared medical
device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
physician. VRT also has CE Marking for the EU. NovaVision also
provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing
visual sensitivity deep within the field defect.
The Company has also developed NeuroEyeCoach™, a therapy which
is highly complementary to VRT™. The two therapies address
different visual disabilities each of which results from
neurologically-induced vision loss – a loss of visual field as well
as difficulty with eye movement, affecting the ability to integrate
visual information. VRT provides partial restoration of the
patient's lost visual field; NeuroEyeCoach™ is designed to increase
the efficiency of eye movement and re-train the patients' ability
to integrate visual information between the left and right hand
side. For an overview of NovaVision see NovaVision Video.
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com, www.vycorvbas.com or www.novavision.com.
Vycor Medical, Inc Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
+1(561)-558-2020
info@vycormedical.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vycor-signs-agreement-with-healthsouth-for-second-novavision-therapy-product-300095371.html
SOURCE Vycor Medical, Inc.
